HEADLINES
Novartis to buy breast cancer drug candidate from Synnovation
Novartis is set to acquire a promising breast cancer drug candidate from Synnovation Therapeutics in a deal worth up to $3 billion, strengthening its oncology pipeline. The experimental therapy targets HR-positive/HER2-negative breast cancer using a next-generation PI3Kα inhibition approach.
Ludwig Burger/Reuters
March 20, 2026
FILE PHOTO: The company's logo is seen at a building of Swiss drugmaker Novartis in Rotkreuz, Switzerland, January 29, 2020.
Arnd Wiegmann/Reuters
Novartis NOVN.S said on Friday it agreed to acquire breast cancer drug candidate SNV4818 from Synnovation Therapeutics for $2 billion upfront and up to $1 billion contingent on further development achievements.
The experimental drug belongs to the class of selective PI3Kα inhibitors, a new approach for the treatment of a type of breast cancer known as HR positive/HER2 negative and potentially other solid tumours.
-Ludwig Burger/Reuters
TOP HEALTH STORIES
Add a Title
How tumor freezing is changing treatment for some breast cancer patients
Kennedy to tout new food policies but skip vaccines in remarks to US Congress
Prince Harry talks mental health with charity workers at Melbourne football club
LATEST NEWS
Add a Title
Uprooted by the war, Lebanese return home to check if their houses are still standing
Celebratory gunfire, fireworks, and victory signs: People return to Lebanon after ceasefire with Israel
Prince Harry and Meghan meet survivors of Bondi Beach attack on final day of Australia trip
PARALUMAN NEWS
GET IN TOUCH
desk@myparaluman.ph
Tektite Towers (East), Exchange Road
Ortigas Center. San Antonio 1600
City of Pasig, NCR, Philippines
MENU
EDITORIAL STANDARDS
© 2025 Paraluman News Publication